Phase 1 First-in-human Study of JS014

NCT05296772 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasm Malignant
Neoplasm, Experimental
Solid Tumor, Adult
Lymphoma

Interventions

BIOLOGICAL: JS014, Interleukin 21 and humanized anti-human serum albumin VHH antibody
BIOLOGICAL: Pembrolizumab - anti-PD-1 antibody

Sponsor

Anwita Biosciences

Collaborators

[object Object]